These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21198541)

  • 1. Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.
    Suratman S; Leach K; Sexton P; Felder C; Loiacono R; Christopoulos A
    Br J Pharmacol; 2011 Apr; 162(7):1659-70. PubMed ID: 21198541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
    Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
    Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).
    Nawaratne V; Leach K; Suratman N; Loiacono RE; Felder CC; Armbruster BN; Roth BL; Sexton PM; Christopoulos A
    Mol Pharmacol; 2008 Oct; 74(4):1119-31. PubMed ID: 18628403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
    Valant C; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.
    Nawaratne V; Leach K; Felder CC; Sexton PM; Christopoulos A
    J Biol Chem; 2010 Jun; 285(25):19012-21. PubMed ID: 20406819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
    Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor.
    Huynh T; Valant C; Crosby IT; Sexton PM; Christopoulos A; Capuano B
    J Med Chem; 2013 Oct; 56(20):8196-200. PubMed ID: 24074052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of M4 muscarinic receptor positive allosteric modulators derived from VU10004.
    Huynh T; Valant C; Crosby IT; Sexton PM; Christopoulos A; Capuano B
    ACS Chem Neurosci; 2015 Jun; 6(6):838-44. PubMed ID: 25857219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY2033298, a positive allosteric modulator at muscarinic M₄ receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms.
    Gannon RL; Millan MJ
    Psychopharmacology (Berl); 2012 Nov; 224(2):231-40. PubMed ID: 22610522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biased Profile of Xanomeline at the Recombinant Human M
    McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
    ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor.
    Leach K; Davey AE; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2011 May; 79(5):855-65. PubMed ID: 21300722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.
    Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
    Chan WY; McKinzie DL; Bose S; Mitchell SN; Witkin JM; Thompson RC; Christopoulos A; Lazareno S; Birdsall NJ; Bymaster FP; Felder CC
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10978-83. PubMed ID: 18678919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics.
    Vuckovic Z; Wang J; Pham V; Mobbs JI; Belousoff MJ; Bhattarai A; Burger WAC; Thompson G; Yeasmin M; Nawaratne V; Leach K; van der Westhuizen ET; Khajehali E; Liang YL; Glukhova A; Wootten D; Lindsley CW; Tobin A; Sexton P; Danev R; Valant C; Miao Y; Christopoulos A; Thal DM
    Elife; 2023 May; 12():. PubMed ID: 37248726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
    Lanzafame AA; Sexton PM; Christopoulos A
    Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Development of Muscarinic Acetylcholine M
    Takai K; Enomoto T
    Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M
    van der Westhuizen ET; Spathis A; Khajehali E; Jörg M; Mistry SN; Capuano B; Tobin AB; Sexton PM; Scammells PJ; Valant C; Christopoulos A
    Mol Pharmacol; 2018 Jul; 94(1):770-783. PubMed ID: 29691279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators.
    Berizzi AE; Gentry PR; Rueda P; Den Hoedt S; Sexton PM; Langmead CJ; Christopoulos A
    Mol Pharmacol; 2016 Oct; 90(4):427-36. PubMed ID: 27461343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.
    Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
    Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.
    Šantrůčková E; Doležal V; El-Fakahany EE; Jakubík J
    PLoS One; 2014; 9(2):e88910. PubMed ID: 24558448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.